Outcome Measures for Clinical Trials in Fragile X Syndrome
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Progress in basic neuroscience has led to identification of molecular targets for treatment in fragile X syndrome (FXS) and other neurodevelopmental disorders; however, there is a gap in translation to targeted therapies in humans. One major obstacle to the demonstration of efficacy in human trials has been the lack of generally accepted endpoints to assess improvement in function in individuals with FXS. To address this problem, the National Institutes of Health convened a meeting of leading scientists and clinicians with the goal of identifying and standardizing outcome measures for use as potential endpoints in clinical trials in FXS. METHODS: Participants in the meeting included FXS experts, experts in the design and implementation of clinical trials and measure development, and representatives from advocacy groups, industry, and federal agencies. RESULTS: The group generated recommendations for optimal outcome measures in cognitive, behavioral, and biomarker/medical domains, including additional testing and validation of existing measures and development of new measures in areas of need. Although no one endpoint or set of endpoints could be identified that met all criteria as an optimal measure, recommendations are presented in this report. CONCLUSION: The report is expected to guide the selection of measures in clinical trials and lead to the use of a more consistent battery of measures across trials. Furthermore, this will help to direct research toward gaps in the development of validated FXS-specific outcome measures and to assist with interpretation of clinical trial data by creating templates for measurement of treatment efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
Randolph, C., Tierney, M. C., Mohr, E., & Chase, T. N. (1998) · Journal of Clinical and Experimental Neuropsychology · doi:10.1076/jcen.20.3.310.823 · Cited by 2,519
FMRP Stalls Ribosomal Translocation on mRNAs Linked to Synaptic Function and Autism
Darnell, J. C., Van Driesche, S. J., Zhang, C., Hung, K. Y. S., Mele, A., Fraser, C. E., Stone, E. F., Chen, C., Fak, J. J., Chi, S. W., et al. (2011) · Cell · doi:10.1016/j.cell.2011.06.013 · Cited by 2,072 · cited 2×
“This research should strive to identify and develop measures that (1) are psychometrically sound with high reliability, validity, and sensitivity to change for the FXS population; (2) index core features of the FXS phenotype, at the neurobiological level or the level of cognition, emotion, and behavior; (3) focus on c…”
BackgroundTEST REVIEW behavior rating inventory of executive function.
Gioia, G. A., Isquith, P. K., Guy, S. C., & Kenworthy, L. (2000) · Child Neuropsychology · doi:10.1076/chin.6.3.235.3152 · Cited by 1,925
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574
Varieties of Repetitive Behavior in Autism: Comparisons to Mental Retardation
Bodfish, J. W., Symons, F. J., Parker, D. E., & Lewis, M. H. (2000) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1005596502855 · Cited by 1,223
SWANSON, J. M., KRAEMER, H. C., HINSHAW, S. P., ARNOLD, L. E., CONNERS, C. K., ABIKOFF, H. B., CLEVENGER, W., DAVIES, M., ELLIOTT, G. R., GREENHILL, L. L., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200102000-00011 · Cited by 1,157
Fragile X Syndrome: Loss of Local mRNA Regulation Alters Synaptic Development and Function
Bassell, G. J., & Warren, S. T. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.004 · Cited by 1,051
Jacquemont, S., Curie, A., des Portes, V., Torrioli, M. G., Berry-Kravis, E., Hagerman, R. J., Ramos, F. J., Cornish, K., He, Y., Paulding, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001708 · Cited by 609
Self-citationAdvances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596
Self-citationThe Pediatric Anxiety Rating Scale (PARS): development and psychometric properties
P, T. R. U. O. P. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200209000-00006 · Cited by 532
Molecular Mechanisms of Fragile X Syndrome: A Twenty-Year Perspective
Santoro, M. R., Bray, S. M., & Warren, S. T. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132457 · Cited by 528
A pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411
Self-citationThe Pathophysiology of Fragile X (and What It Teaches Us about Synapses)
Bhakar, A. L., Dölen, G., & Bear, M. F. (2012) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-153138 · Cited by 370 · cited 2×
“This research should strive to identify and develop measures that (1) are psychometrically sound with high reliability, validity, and sensitivity to change for the FXS population; (2) index core features of the FXS phenotype, at the neurobiological level or the level of cognition, emotion, and behavior; (3) focus on c…”
BackgroundBerry-Kravis, E. M., Hessl, D., Rathmell, B., Zarevics, P., Cherubini, M., Walton-Bowen, K., Mu, Y., Nguyen, D. V., Gonzalez-Heydrich, J., Wang, P. P., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004214 · Cited by 328
Self-citationRescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313
Executive function in adolescents with Down Syndrome
Lanfranchi, S., Jerman, O., Dal Pont, E., Alberti, A., & Vianello, R. (2010) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2010.01262.x · Cited by 308
Open-label add-on treatment trial of minocycline in fragile X syndrome.
Paribello, C., Tao, L., Folino, A., Berry-Kravis, E., Tranfaglia, M., Ethell, I. M., & Ethell, D. W. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-91 · Cited by 223
Self-citationARNOLD, L. E., VITIELLO, B., MCDOUGLE, C., SCAHILL, L., SHAH, B., GONZALEZ, N. M., CHUANG, S., DAVIES, M., HOLLWAY, J., AMAN, M. G., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200312000-00011 · Cited by 218
Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215
Self-citationFernandez-Carvajal, I., Walichiewicz, P., Xiaosen, X., Pan, R., Hagerman, P. J., & Tassone, F. (2009) · The Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080173 · Cited by 204 · cited 7×
“Working groups were created to identify outcome measures in 3 areas relevant to the broad phenotype of fragile X syndrome (FXS): (1) Cognition, (2) Behavior/ Emotion, and (3) Medical/Physical including Biomarkers (Fig.”
BackgroundInfluentialAltered mTOR signaling and enhanced CYFIP2 expression levels in subjects with fragile X syndrome
Hoeffer, C. A., Sanchez, E., Hagerman, R. J., Mu, Y., Nguyen, D. V., Wong, H., Whelan, A. M., Zukin, R. S., Klann, E., & Tassone, F. (2012) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2012.00768.x · Cited by 198
A controlled trial of stimulant medication in children with the fragile X syndrome
Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320300138 · Cited by 158
Berry-Kravis, E., Krause, S. E., Block, S. S., Guter, S., Wuu, J., Leurgans, S., Decle, P., Potanos, K., Cook, E., Salt, J., et al. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.525 · Cited by 155
Self-citationPsychopharmacology in fragile X syndrome—Present and future
Berry‐Kravis, E., & Potanos, K. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20007 · Cited by 151
Self-citationEffects of intranasal oxytocin on social anxiety in males with fragile X syndrome
Hall, S. S., Lightbody, A. A., McCarthy, B. E., Parker, K. J., & Reiss, A. L. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2011.07.020 · Cited by 143
Self-citationReversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1KO Mice
Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., Abozeid, S. H., Stein, K. M., Stodola, L. A., Tranfaglia, M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026549 · Cited by 110
Self-citationTorrioli, M. G., Vernacotola, S., Peruzzi, L., Tabolacci, E., Mila, M., Militerni, R., Musumeci, S., Ramos, F. J., Frontera, M., Sorge, G., et al. (2008) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.32268 · Cited by 100
Treatment with valproic acid ameliorates ADHD symptoms in fragile X syndrome boys
Torrioli, M., Vernacotola, S., Setini, C., Bevilacqua, F., Martinelli, D., Snape, M., Hutchison, J. A., Di Raimo, F. R., Tabolacci, E., & Neri, G. (2010) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33484 · Cited by 71
A prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69
Aberrant Brain Activation During Gaze Processing in Boys With Fragile X Syndrome
Watson, C., Hoeft, F., Garrett, A. S., Hall, S. S., & Reiss, A. L. (2008) · Archives of General Psychiatry · doi:10.1001/archpsyc.65.11.1315 · Cited by 65
Self-citationSocial cognition skills among females with fragile X
Mazzocco, M. M. M., Pennington, B. F., & Hagerman, R. J. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172129 · Cited by 46
Autonomic regulation in fragile X syndrome
Heilman, K. J., Harden, E. R., Zageris, D. M., Berry‐Kravis, E., & Porges, S. W. (2011) · Developmental Psychobiology · doi:10.1002/dev.20551 · Cited by 42
Self-citation
Cited by
Hagerman, R. J., Berry-Kravis, E., Hazlett, H. C., Bailey, D. B., Moine, H., Kooy, R. F., Tassone, F., Gantois, I., Sonenberg, N., Mandel, J. L., et al. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.65 · Cited by 838
Self-citationOutcome Measures for Clinical Trials in Down Syndrome
Esbensen, A. J., Hooper, S. R., Fidler, D., Hartley, S. L., Edgin, J., d'Ardhuy, X. L., Capone, G., Conners, F. A., Mervis, C. B., Abbeduto, L., et al. (2017) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-122.3.247 · Cited by 153
Self-citationFragXis Study Group, Youssef, E. A., Berry-Kravis, E., Czech, C., Hagerman, R. J., Hessl, D., Wong, C. Y., Rabbia, M., Deptula, D., John, A., et al. (2018) · Neuropsychopharmacology · doi:10.1038/npp.2017.177 · Cited by 133
Self-citationTherapeutic Strategies in Fragile X Syndrome: From Bench to Bedside and Back
Gross, C., Hoffmann, A., Bassell, G. J., & Berry-Kravis, E. M. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0355-9 · Cited by 105
Self-citationBerry-Kravis, E., Horrigan, J. P., Tartaglia, N., Hagerman, R., Kolevzon, A., Erickson, C. A., Hatti, S., Snape, M., Yaroshinsky, A., Stoms, G., et al. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.04.019 · Cited by 102
Self-citation
Metadata
- Authors
- Berry-Kravis, E., Hessl, D., Abbeduto, L., Reiss, A. L., Beckel-Mitchener, A., & Urv, T. K.
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2013-09
- Volume
- 34
- Issue
- 7
- Pages
- 508-522
- ISSN
- 0196-206X (ISSN-L)
- OpenAlex
- W2044352563
- Cited by
- 154
- References
- 33
- FWCI
- 8.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.